Concerns Over Private Equity’s Role in Cancer Care
A recent report from the Bull Moose Project highlights how private equity firms have been quietly taking control of significant segments of the U.S. cancer care system. The findings raise alarms over increasing costs, diminishing quality, and the erosion of physician independence.
The report reveals that, for the past two decades, these investor-backed entities have consolidated oncology clinics, imaging facilities, specialty pharmacies, and billing operations into a vast corporate network. As a result, what was once predominantly managed by healthcare professionals is now largely influenced by financial firms focused on profit.
According to the Bull Moose Project, cancer treatments attract interest from Wall Street due to consistent demand and Medicare reimbursement policies that often favor expensive drugs and interventions. Reports suggest that private equity firms have acquired numerous oncology practices nationwide, altering who governs care delivery and the decision-making processes involved.
However, the implications of these acquisitions extend beyond mere administrative changes; they shift incentives in ways that can directly affect patients. Studies referenced in the report indicate that private equity ownership in oncology correlates with steeper price increases than in any other medical specialty, coupled with deteriorating outcomes in certain procedures. Patients may face higher complication and mortality rates for some cancer surgeries, while doctors are pressured to see more patients in less time and to opt for costlier treatments.
Furthermore, the report indicates that low-income and rural communities are bearing the brunt of these changes. The pressure from corporate consolidation could limit patient choices and destabilize local healthcare access.
The report also outlines various scandals associated with private equity-backed cancer care providers, including allegations of fraud, kickbacks, data breaches, and bankruptcy, which may leave patients without critical services.
In light of private equity’s growing influence, lawmakers and regulators are starting to take notice, revisiting antitrust laws and exploring measures to curb corporate control over drugs. Still, the report emphasizes that the industry is actively lobbying against these reform efforts.
The Bull Moose Project’s message is clear: without stronger oversight, the focus of cancer care might shift away from patient wellbeing, leaning more toward maximizing profits during what are often the most vulnerable moments of patients’ lives.
